reported that long‐chain acyl‐CoA synthetase 1 (ACSL1) overexpression enhanced the proliferation‐inhibiting effects of imatinib in CML cells.83 The gene discussed is ACSL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.